

## REFERENCES USED IN ALGORITHMS FOR THE TREATMENT OF PERSONS WITH CHRONIC PAIN

1. AA Pharm Inc: **Aventyl (nortriptyline)**. In: *CA Product Monograph*. Vaughan, ON; 2014.
2. AA Pharma Inc: **Elavil (amitriptyline)**. In: *CA Product Monograph*. Vaughan, ON; 2010.
3. AA Pharma Inc: **Ketoprofen**. In: *CA Product Monograph*. Vaughan, ON; 2011.
4. AA Pharma Inc: **Desipramine**. In: *CA Product Monograph*. Vaughan, ON; 2012.
5. Actavis Kadian LLC: **Kadian (morphine)**. In: *US Product Monograph*. Parsippany, NJ; 2014.
6. Agundez JA, Garcia-Martin E, Martinez C: **Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?** *Expert Opin Drug Metab Toxicol* 2009, **5**(6):607-620.
7. Aithal GP, Day CP, Leathart JB, Daly AK: **Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis**. *Pharmacogenetics* 2000, **10**(6):511-518.
8. Alfirevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK, Pirmohamed M: **HLA-B locus in Caucasian patients with carbamazepine hypersensitivity**. *Pharmacogenomics* 2006, **7**(6):813-818.
9. Almatica Pharma Inc: **Naprelan (naproxen sodium)**. In: *US Product Monograph*. Pine Brook, NJ; 2017.
10. Amstutz U, Ross CJ, Castro-Pastrana LI, Rieder MJ, Shear NH, Hayden MR, Carleton BC: **HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children**. *Clinical pharmacology and therapeutics* 2013, **94**(1):142-149.
11. Amstutz U, Shear NH, Rieder MJ, Hwang S, Fung V, Nakamura H, Connolly MB, Ito S, Carleton BC: **Recommendations for HLA-B\*15:02 and HLA-A\*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions**. *Epilepsia* 2014, **55**(4):496-506.
12. An DM, Wu XT, Hu FY, Yan B, Stefan H, Zhou D: **Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B\*1502 in a Han Chinese population**. *Epilepsy research* 2010, **92**(2-3):226-230.
13. Aphenia Pharma Solutions: **IBU (ibuprofen)**. In: *US Product Monograph*. Cookeville, TN USA; 2017.
14. Apotex Inc: **Apo-Carbamazepine**. In: *CA Product Monograph*. Toronto, ON; 2014.
15. Apotex Inc: **Apo-Ibuprofen**. In: *CA Product Monograph*. Toronto, ON; 2017.
16. Apotex Inc: **Apo-amitriptyline**. In: *CA Product Monograph*. Toronto, ON; 2019.

17. Arafat MH, Atteia HH: **Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6) are associated with long term tramadol treatment-induced oxidative damage and hepatotoxicity.** *Toxicol Appl Pharmacol* 2018, **346**:37-44.
18. AstraZeneca Canada Inc: **Vimovo (naproxen / esomeprazole).** In: *CA Product Monograph*. Mississauga, ON; 2018.
19. Atkinson JH, Slater MA, Capparelli EV, Wallace MS, Zisook S, Abramson I, Matthews SC, Garfin SR: **Efficacy of noradrenergic and serotonergic antidepressants in chronic back pain: a preliminary concentration-controlled trial.** *Journal of clinical psychopharmacology* 2007, **27**(2):135-142.
20. Aubrun F, Zahr N, Langeron O, Boccheciampe N, Cozic N, Belin L, Hulot JS, Khiami F, Riou B: **Opioid-related genetic polymorphisms do not influence postoperative opioid requirement: A prospective observational study.** *Eur J Anaesthesiol* 2018, **35**(7):496-504.
21. Bally M, Dendukuri N, Rich B, Nadeau L, Helin-Salmivaara A, Garbe E, Brophy JM: **Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data.** *BMJ* 2017, **357**:j1909.
22. Bayer Inc: **Aleve (naproxen).** In: *CA Product Monograph*. Mississauga, ON; 2017.
23. BC Renal Agency: **Renal Analgesic Brochure.** In.: BC Renal Agency; 2011.
24. Benson GD, Koff RS, Tolman KG: **The therapeutic use of acetaminophen in patients with liver disease.** *American journal of therapeutics* 2005, **12**(2):133-141.
25. Bhalra N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA *et al*: **Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.** *Lancet (London, England)* 2013, **382**(9894):769-779.
26. Brandl EJ, Tiwari AK, Zhou X, Deluce J, Kennedy JL, Muller DJ, Richter MA: **Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder.** *The pharmacogenomics journal* 2014, **14**(2):176-181.
27. Bristol-Myers Squibb: **Percocet/Percocet-Demi** In: *CA Product Monograph*. Ottawa, ON; 2014.
28. Burmester G, Lanar A, Biasucci L, Hermann M, Lohmander S, Olivieri I, Scarpignato C, Smolen J, Hawkey C, Bajkowski A *et al*: **The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel.** *Annals of the rheumatic diseases* 2011, **70**(5):818-822.
29. Busch AJ, Barber KA, Overend TJ, Peloso PM, Schachter CL: **Exercise for treating fibromyalgia syndrome.** *The Cochrane database of systematic reviews* 2007(4):CD003786.
30. Busch AJ, Webber SC, Richards RS, Bidonde J, Schachter CL, Schafer LA, Danyliw A, Sawant A, Dal Bello-Haas V, Rader T *et al*: **Resistance exercise training for fibromyalgia.** *The Cochrane database of systematic reviews* 2013(12):CD010884.

31. Campa D, Gioia A, Tomei A, Poli P, Barale R: **Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief.** *Clinical pharmacology and therapeutics* 2008, **83**(4):559-566.
32. Canadian Pharmacists Association: **Nonsteroidal Anti-inflammatory Drugs [CPhA monograph]**. In: *RxTx*. Ottawa, ON; 2014.
33. Canadian Pharmacists Association: **Lamotrigine [CPhA monograph]**. In: *RxTx*. Ottawa, ON; 2015.
34. Canadian Pharmacists Association: **Tricyclic Antidepressants [CPhA Monograph]**. In: *RxTx*. Ottawa, ON; 2016.
35. Canadian Pharmacists Association: **Acetaminophen [CPhA monograph]**. In: *RxTx*. Ottawa, ON; 2016.
36. Crette S, Bell MJ, Reynolds WJ, Haraoui B, McCain GA, Bykerk VP, Edworthy SM, Baron M, Koehler BE, Fam AG *et al*: **Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial.** *Arthritis and rheumatism* 1994, **37**(1):32-40.
37. Carlsbad Technology Inc: **Diclofenac Sodium (Delayed Release)**. In: *US Product Monograph*. Carlsbad, CA; 2016.
38. Caudle KE, Dunnenberger HM, Freimuth RR, Peterson JF, Burlison JD, Whirl-Carrillo M, Scott SA, Rehm HL, Williams MS, Klein TE *et al*: **Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC).** *Genetics in medicine : official journal of the American College of Medical Genetics* 2017, **19**(2):215-223.
39. Cawston H, Davie A, Paget MA, Skljarevski V, Happich M: **Efficacy of duloxetine versus alternative oral therapies: an indirect comparison of randomised clinical trials in chronic low back pain.** *European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society* 2013, **22**(9):1996-2009.
40. Chang CC, Too CL, Murad S, Hussein SH: **Association of HLA-B\*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population.** *International journal of dermatology* 2011, **50**(2):221-224.
41. Chang Y, Yang LY, Zhang MC, Liu SY: **Correlation of the UGT1A4 gene polymorphism with serum concentration and therapeutic efficacy of lamotrigine in Han Chinese of Northern China.** *European journal of clinical pharmacology* 2014, **70**(8):941-946.
42. Chaparro LE, Wiffen PJ, Moore RA, Gilron I: **Combination pharmacotherapy for the treatment of neuropathic pain in adults.** *The Cochrane database of systematic reviews* 2012, **7**:CD008943.
43. Chen CB, Hsiao YH, Wu T, Hsieh MS, Tassaneeyakul W, Jorns TP, Sukasem C, Hsu CN, Su SC, Chang WC *et al*: **Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians.** *Neurology* 2017, **88**(1):78-86.

44. Cheung YK, Cheng SH, Chan EJ, Lo SV, Ng MH, Kwan P: **HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese.** *Epilepsia* 2013, **54**(7):1307-1314.
45. Choi SW, Lam DMH, Wong SSC, Shiu HHC, Wang AXM, Cheung CW: **Effects of single nucleotide polymorphisms on surgical and postsurgical opioid requirements: a systematic review and meta-analysis.** *The Clinical journal of pain* 2017, **33**(12):1117-1130.
46. Chong KW, Chan DW, Cheung YB, Ching LK, Hie SL, Thomas T, Ling S, Tan EC: **Association of carbamazepine-induced severe cutaneous drug reactions and HLA-B\*1502 allele status, and dose and treatment duration in paediatric neurology patients in Singapore.** *Archives of disease in childhood* 2014, **99**(6):581-584.
47. Chou R, Qaseem A, Snow V, Casey D, Cross JT, Jr., Shekelle P, Owens DK, Clinical Efficacy Assessment Subcommittee of the American College of P, American College of P, American Pain Society Low Back Pain Guidelines P: **Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society.** *Annals of internal medicine* 2007, **147**(7):478-491.
48. Chung WH, Hung SI, Hong HS, Hsieh MS, Yang LC, Ho HC, Wu JY, Chen YT: **Medical genetics: a marker for Stevens-Johnson syndrome.** *Nature* 2004, **428**(6982):486.
49. Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, Haidar CE, Shen DD, Callaghan JT, Sadhasivam S *et al*: **Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.** *Clinical pharmacology and therapeutics* 2014, **95**(4):376-382.
50. Cruccu G, Gronseth G, Alksne J, Argoff C, Brainin M, Burchiel K, Nurmikko T, Zakrzewska JM: **AAN-EFNS guidelines on trigeminal neuralgia management.** *European journal of neurology* 2008, **15**(10):1013-1028.
51. Daci A, Beretta G, Vllasaliu D, Shala A, Govori V, Norata GD, Krasniqi S: **Polymorphic Variants of SCN1A and EPHX1 Influence Plasma Carbamazepine Concentration, Metabolism and Pharmacoresistance in a Population of Kosovar Albanian Epileptic Patients.** *PLoS one* 2015, **10**(11):e0142408.
52. De Gregori M, Diatchenko L, Ingelmo PM, Napolioni V, Klepstad P, Belfer I, Molinaro V, Garbin G, Ranzani GN, Alberio G *et al*: **Human genetic variability contributes to postoperative morphine consumption.** *The journal of pain : official journal of the American Pain Society* 2016, **17**(5):628-636.
53. Depomed Inc: **Gralise (gabapentin).** In: *US Product Monograph.* Newark, CA; 2015.
54. Derry S, Moore RA: **Topical capsaicin (low concentration) for chronic neuropathic pain in adults.** *The Cochrane database of systematic reviews* 2012, **9**:CD010111.
55. Derry S, Wiffen PJ, Moore RA, Quinlan J: **Topical lidocaine for neuropathic pain in adults.** *The Cochrane database of systematic reviews* 2014, **7**:CD010958.

56. Dong H, Lu SJ, Zhang R, Liu DD, Zhang YZ, Song CY: **Effect of the CYP2D6 gene polymorphism on postoperative analgesia of tramadol in Han nationality nephrectomy patients.** *European journal of clinical pharmacology* 2015, **71**(6):681-686.
57. Dowell D, Haegerich TM, Chou R: **CDC Guideline for Prescribing Opioids for Chronic Pain-- United States, 2016.** *Jama* 2016, **315**(15):1624-1645.
58. **Pharmacogenomics guidelines** [<https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf>]
59. Eap CB, Lessard E, Baumann P, Brawand-Amey M, Yessine MA, O'Hara G, Turgeon J: **Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans.** *Pharmacogenetics* 2003, **13**(1):39-47.
60. Eli Lilly and Company: **Cymbalta (duloxetine).** In: *US Product Monograph.* Indianapolis , IN; 2017.
61. Eli Lilly Canada Inc: **Cymbalta (duloxetine).** In: *CA Product Monograph.* Toronto, ON; 2016.
62. Endo Pharmaceuticals Inc: **Percocet (oxycodone /acetaminophen).** In: *US Product Monograph.* Malvern, PA; 2018.
63. Endo Pharmaceuticals Inc: **Voltaren (diclofenac sodium gel).** In: *US Product Monograph.* Warren, NJ; 2018.
64. Enthoven WT, Roelofs PD, Deyo RA, van Tulder MW, Koes BW: **Non-steroidal anti-inflammatory drugs for chronic low back pain.** *The Cochrane database of systematic reviews* 2016, **2**:CD012087.
65. Figueiras A, Estany-Gestal A, Aguirre C, Ruiz B, Vidal X, Carvajal A, Salado I, Salgado-Barreira A, Rodella L, Moretti U *et al*: **CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding: a case-control study.** *Pharmacogenetics and genomics* 2016, **26**(2):66-73.
66. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpaa M, Hansson P, Jensen TS *et al*: **Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis.** *The Lancet Neurology* 2015, **14**(2):162-173.
67. Fitzcharles MA, Ste-Marie PA, Goldenberg DL, Pereira JX, Abbey S, Choiniere M, Ko G, Moulin DE, Panopalis P, Proulx J *et al*: **2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary.** *Pain research & management : the journal of the Canadian Pain Society = journal de la societe canadienne pour le traitement de la douleur* 2013, **18**(3):119-126.
68. Freynhagen R, Geisslinger G, Schug SA: **Opioids for chronic non-cancer pain.** *BMJ* 2013, **346**:f2937.
69. Fricke-Galindo I, Martinez-Juarez IE, Monroy-Jaramillo N, Jung-Cook H, Falfan-Valencia R, Ortega-Vazquez A, Alonso-Vilatela ME, Lopez-Lopez M: **HLA-A\*02:01:01/-B\*35:01:01/-**

- C\*04:01:01 haplotype associated with lamotrigine-induced maculopapular exanthema in Mexican Mestizo patients.** *Pharmacogenomics* 2014, **15**(15):1881-1891.
70. Fukuda T, Yamamoto I, Nishida Y, Zhou Q, Ohno M, Takada K, Azuma J: **Effect of the CYP2D6\*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers.** *British journal of clinical pharmacology* 1999, **47**(4):450-453.
  71. Fukuda T, Nishida Y, Zhou Q, Yamamoto I, Kondo S, Azuma J: **The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population.** *European journal of clinical pharmacology* 2000, **56**(2):175-180.
  72. Fukuda K, Hayashida M, Ide S, Saita N, Kokita Y, Kasai S, Nishizawa D, Ogai Y, Hasegawa J, Nagashima M *et al*: **Association between OPRM1 gene polymorphisms and fentanyl sensitivity in patients undergoing painful cosmetic surgery.** *Pain* 2009, **147**(1-3):194-201.
  73. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS: **The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype.** *Clinical pharmacology and therapeutics* 2008, **83**(2):234-242.
  74. GD Searle LLC Division of Pfizer Inc: **Celebrex (celecoxib)** In: *US Product Monograph*. New York, NY: ; 2018.
  75. Genentech Inc: **Naproxen**. In: *US Product Monograph*. South San Francisco, CA; 2010.
  76. Genin E, Chen DP, Hung SI, Sekula P, Schumacher M, Chang PY, Tsai SH, Wu TL, Bellon T, Tamouza R *et al*: **HLA-A\*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis.** *The pharmacogenomics journal* 2014, **14**(3):281-288.
  77. Gill D, Derry S, Wiffen PJ, Moore RA: **Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults.** *The Cochrane database of systematic reviews* 2011(10):CD009183.
  78. Gilron I, Jensen TS, Dickenson AH: **Combination pharmacotherapy for management of chronic pain: from bench to bedside.** *The Lancet Neurology* 2013, **12**(11):1084-1095.
  79. Ginosar Y, Davidson EM, Meroz Y, Blotnick S, Shacham M, Caraco Y: **Mu-opioid receptor (A118G) single-nucleotide polymorphism affects alfentanil requirements for extracorporeal shock wave lithotripsy: a pharmacokinetic-pharmacodynamic study.** *British journal of anaesthesia* 2009, **103**(3):420-427.
  80. GlaxoSmithKline Inc.: **Lamictal (lamotrigine)**. In: *CA Product Monograph*. Mississauga, ON; 2016.
  81. GlaxoSmithKline LLC: **Lamictal (lamotrigine)**. In: *US Product Monograph*. Research Triangle Park, NC; 2017.
  82. Glombiewski JA, Sawyer AT, Gutermann J, Koenig K, Rief W, Hofmann SG: **Psychological treatments for fibromyalgia: a meta-analysis.** *Pain* 2010, **151**(2):280-295.

83. Goldenberg DL, Burckhardt C, Crofford L: **Management of fibromyalgia syndrome.** *Jama* 2004, **292**(19):2388-2395.
84. Griffin MR: **High-dose non-steroidal anti-inflammatories: painful choices.** *Lancet (London, England)* 2013, **382**(9894):746-748.
85. Gronseth G, Cruccu G, Alksne J, Argoff C, Brainin M, Burchiel K, Nurmikko T, Zakrzewska JM: **Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the European Federation of Neurological Societies.** *Neurology* 2008, **71**(15):1183-1190.
86. Grover S, Kukreti R: **HLA alleles and hypersensitivity to carbamazepine: an updated systematic review with meta-analysis.** *Pharmacogenetics and genomics* 2014, **24**(2):94-112.
87. Haerian BS, Baum L, Kwan P, Tan HJ, Raymond AA, Mohamed Z: **SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis.** *Pharmacogenomics* 2013, **14**(10):1153-1166.
88. Haslemo T, Eliasson E, Jukic MM, Ingelman-Sundberg M, Molden E: **Significantly lower CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6\*41 versus CYP2D6\*9 or CYP2D6\*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients.** *British journal of clinical pharmacology* 2019, **85**(1):194-201.
89. Hauser W, Petzke F, Sommer C: **Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome.** *The journal of pain : official journal of the American Pain Society* 2010, **11**(6):505-521.
90. He N, Min FL, Shi YW, Guo J, Liu XR, Li BM, Zhou JH, Ou YM, Liao JX, Liao WP: **Cutaneous reactions induced by oxcarbazepine in Southern Han Chinese: incidence, features, risk factors and relation to HLA-B alleles.** *Seizure* 2012, **21**(8):614-618.
91. He XJ, Jian LY, He XL, Wu Y, Xu YY, Sun XJ, Miao LY, Zhao LM: **Association between the HLA-B\*15:02 allele and carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Han individuals of northeastern China.** *Pharmacological reports : PR* 2013, **65**(5):1256-1262.
92. Heritage Pharmaceuticals Inc: **Ketoprofen** In: *US Product Monograph.* East Brunswick, NJ 2018.
93. Hermann M, Hendset M, Fosaas K, Hjerpset M, Refsum H: **Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6\*3, \*4 or \*5 allele.** *European journal of clinical pharmacology* 2008, **64**(5):483-487.
94. Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Muller DJ, Shimoda K, Bishop JR, Kharasch ED, Skaar TC, Gaedigk A *et al*: **Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.** *Clinical pharmacology and therapeutics* 2017, **102**(1):37-44.

95. Horizon Pharma USA Inc: **Pennsaid (diclofenac sodium)**. In: *US Product Monograph*. Lake Forest, IL; 2016.
96. Horizon Pharma USA Inc: **Vimovo (naproxen / esomeprazole magnesium)**. In: *US Product Monograph*. Lake Forest, IL; 2018.
97. Hsiao YH, Hui RC, Wu T, Chang WC, Hsieh MS, Yang CH, Ho HC, Chang YG, Chen MJ, Lin JY *et al*: **Genotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations**. *Journal of dermatological science* 2014, **73**(2):101-109.
98. Hu FY, Wu XT, An DM, Yan B, Stefan H, Zhou D: **Pilot association study of oxcarbazepine-induced mild cutaneous adverse reactions with HLA-B\*1502 allele in Chinese Han population**. *Seizure* 2011, **20**(2):160-162.
99. Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, Lee WR, Hu SL, Wu MT, Chen GS, Wong TW *et al*: **Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions**. *Pharmacogenetics and genomics* 2006, **16**(4):297-306.
100. Hung SI, Chung WH, Liu ZS, Chen CH, Hsieh MS, Hui RC, Chu CY, Chen YT: **Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese**. *Pharmacogenomics* 2010, **11**(3):349-356.
101. Hung CC, Chiou MH, Huang BH, Hsieh YW, Hsieh TJ, Huang CL, Lane HY: **Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients**. *Pharmacogenomics* 2011, **12**(11):1525-1533.
102. Hung CC, Chang WL, Ho JL, Tai JJ, Hsieh TJ, Huang HC, Hsieh YW, Liou HH: **Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization**. *Pharmacogenomics* 2012, **13**(2):159-169.
103. Inoue K, Yamamoto Y, Suzuki E, Takahashi T, Umemura A, Takahashi Y, Imai K, Inoue Y, Hirai K, Tsuji D *et al*: **Factors that influence the pharmacokinetics of lamotrigine in Japanese patients with epilepsy**. *European journal of clinical pharmacology* 2016, **72**(5):555-562.
104. Ito A, Shimada H, Ishikawa K, Takeo N, Hatano Y, Katagiri K, Kohno K, Araki Y, Terao T, Kojima H *et al*: **Association between HLA-DRB1\*0405, -DQB1\*0401 and -DQA1\*0303 alleles and lamotrigine-induced cutaneous adverse drug reactions. A pilot case-control study from Japan**. *Journal of affective disorders* 2015, **179**:47-50.
105. Janssen Inc: **Ultram (tramadol hydrochloride)**. In: *CA Product Monograph*. Toronto, ON; 2018.
106. Janssen Inc: **Tramacet (tramadol hydrochloride / acetaminophen)**. In: *CA Product Monograph*. Toronto, ON; 2018.
107. Janssen Pharmaceuticals Inc: **Ultracet (tramadol hydrochloride / acetaminophen)** In: *US Product Monograph*. Titusville, NJ; 2017.
108. Janssen Pharmaceuticals Inc: **Tylenol with Codeine (acetaminophen / codeine phosphate)**. In: *US Product Monograph*. Titusville, NJ; 2018.



109. Janssen Pharmaceuticals Inc: **Ultram (tramadol)**. In: *US Product Monograph*. Titusville, NJ; 2018.
110. Johnson & Johnson Consumer Inc: **Tylenol 8hr Arthritis (acetaminophen ER)**. In: *US Product Monograph*. Washington, PA; 2018.
111. Jorns TP, Zakrzewska JM: **Evidence-based approach to the medical management of trigeminal neuralgia**. *British journal of neurosurgery* 2007, **21**(3):253-261.
112. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Furuya H, Takahashi Y, Muramatsu M, Kinoshita S *et al*: **HLA-B\*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients**. *Epilepsia* 2010, **51**(12):2461-2465.
113. Kashiwagi M, Aihara M, Takahashi Y, Yamazaki E, Yamane Y, Song Y, Muramatsu M, Ikezawa Z: **Human leukocyte antigen genotypes in carbamazepine-induced severe cutaneous adverse drug response in Japanese patients**. *The Journal of dermatology* 2008, **35**(10):683-685.
114. Kazeem GR, Cox C, Aponte J, Messenheimer J, Brazell C, Nelsen AC, Nelson MR, Foot E: **High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients**. *Pharmacogenetics and genomics* 2009, **19**(9):661-665.
115. Kean WF, Kean CA, Hogan MG: **Osteoarthritis**. In: *Therapeutics*. Edited by Jovaisas B. Ottawa (ON): Canadian Pharmacists Association; 2015.
116. Khor AH, Lim KS, Tan CT, Wong SM, Ng CC: **HLA-B\*15:02 association with carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in an Indian population: a pooled-data analysis and meta-analysis**. *Epilepsia* 2014, **55**(11):e120-124.
117. Kim SH, Lee KW, Song WJ, Kim SH, Jee YK, Lee SM, Kang HR, Park HW, Cho SH, Park SH *et al*: **Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans**. *Epilepsy research* 2011, **97**(1-2):190-197.
118. Kim BK, Jung JW, Kim TB, Chang YS, Park HS, Moon J, Lee ST, Jung KH, Jung KY, Chu K *et al*: **HLA-A\*31:01 and lamotrigine-induced severe cutaneous adverse drug reactions in a Korean population**. *Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology* 2017, **118**(5):629-630.
119. Kim SH, Kim DH, Byeon JY, Kim YH, Kim DH, Lim HJ, Lee CM, Whang SS, Choi CI, Bae JW *et al*: **Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite**. *Archives of pharmacal research* 2017, **40**(3):382-390.
120. Kirchheiner J, Stormer E, Meisel C, Steinbach N, Roots I, Brockmoller J: **Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites**. *Pharmacogenetics* 2003, **13**(8):473-480.
121. Kirchheiner J, Meineke I, Steinbach N, Meisel C, Roots I, Brockmoller J: **Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans**. *British journal of clinical pharmacology* 2003, **55**(1):51-61.

122. Kowa Pharmaceuticals America Inc: **Cambia (diclofenac potassium)**. In: *US Product Monograph*. Montgomery, AL; 2009.
123. Kuijpers T, van Middelkoop M, Rubinstein SM, Ostelo R, Verhagen A, Koes BW, van Tulder MW: **A systematic review on the effectiveness of pharmacological interventions for chronic non-specific low-back pain**. *European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society* 2011, **20**(1):40-50.
124. Kulkantrakorn K, Tassaneeyakul W, Tiamkao S, Jantararoungtong T, Prabmechai N, Vannaprasaht S, Chumworathayi P, Chen P, Sritipsukho P: **HLA-B\*1502 strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain**. *Pain practice : the official journal of World Institute of Pain* 2012, **12**(3):202-208.
125. Laboratoire Riva Inc: **Codeine**. In: *CA Product Monograph*. Blainville, QC; 2018.
126. Landau R, Kern C, Columb MO, Smiley RM, Blouin JL: **Genetic variability of the mu-opioid receptor influences intrathecal fentanyl analgesia requirements in laboring women**. *Pain* 2008, **139**(1):5-14.
127. Lanza FL, Chan FK, Quigley EM: **Guidelines for prevention of NSAID-related ulcer complications**. *The American journal of gastroenterology* 2009, **104**(3):728-738.
128. Leckband SG, Kelsoe JR, Dunnenberger HM, George AL, Jr., Tran E, Berger R, Muller DJ, Whirl-Carrillo M, Caudle KE, Pirmohamed M *et al*: **Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing**. *Clinical pharmacology and therapeutics* 2013, **94**(3):324-328.
129. Lessard E, Yessine MA, Hamelin BA, O'Hara G, LeBlanc J, Turgeon J: **Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans**. *Pharmacogenetics* 1999, **9**(4):435-443.
130. Lexicomp: **Diclofenac (Systemic)**. In: *Lexi-Drugs*. Hudson, Ohio: Wolters Kluwer Health; 2018.
131. Lexicomp: **Ibuprofen**. In: *Lexi-Drugs*. Hudson, Ohio: Wolters Kluwer Health; 2018.
132. Lexicomp: **Naproxen**. In: *Lexi-Drugs*. Hudson, Ohio: Wolters Kluwer Health.; 2018.
133. Li LJ, Hu FY, Wu XT, An DM, Yan B, Zhou D: **Predictive markers for carbamazepine and lamotrigine-induced maculopapular exanthema in Han Chinese**. *Epilepsy research* 2013, **106**(1-2):296-300.
134. Lin XQ, Wang P, Cai WK, Xu GL, Yang M, Zhou MD, Sun M, He F, He GH: **The associations between CYP2D6 metabolizer status and pharmacokinetics and clinical outcomes of venlafaxine: a systematic review and meta-analysis**. *Pharmacopsychiatry* 2019, **52**(5):222-231.

135. Liu YC, Wang WS: **Human mu-opioid receptor gene A118G polymorphism predicts the efficacy of tramadol/acetaminophen combination tablets (ultracet) in oxaliplatin-induced painful neuropathy.** *Cancer* 2012, **118**(6):1718-1725.
136. Liu R, Gong C, Tao L, Yang W, Zheng X, Ma P, Ding L: **Influence of genetic polymorphisms on the pharmacokinetics of celecoxib and its two main metabolites in healthy Chinese subjects.** *European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences* 2015, **79**:13-19.
137. Lobello KW, Preskorn SH, Guico-Pabia CJ, Jiang Q, Paul J, Nichols AI, Patroneva A, Ninan PT: **Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder.** *The Journal of clinical psychiatry* 2010, **71**(11):1482-1487.
138. Lochareernkul C, Loplumlert J, Limotai C, Korkij W, Desudchit T, Tongkobpetch S, Kangwanshiratada O, Hirankarn N, Suphapeetiporn K, Shotelersuk V: **Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B\*1502 allele in Thai population.** *Epilepsia* 2008, **49**(12):2087-2091.
139. Lotsch J, Rohrbacher M, Schmidt H, Doehring A, Brockmoller J, Geisslinger G: **Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation?** *Pain* 2009, **144**(1-2):119-124.
140. Lotsch J, von Hentig N, Freynhagen R, Griessinger N, Zimmermann M, Doehring A, Rohrbacher M, Sittl R, Geisslinger G: **Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers.** *Pharmacogenetics and genomics* 2009, **19**(6):429-436.
141. Lunn MP, Hughes RA, Wiffen PJ: **Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia.** *The Cochrane database of systematic reviews* 2014, **1**:CD007115.
142. Lv YD, Min FL, Liao WP, He N, Zeng T, Ma DH, Shi YW: **The association between oxcarbazepine-induced maculopapular eruption and HLA-B alleles in a northern Han Chinese population.** *BMC neurology* 2013, **13**:75.
143. Ma CL, Wu XY, Zheng J, Wu ZY, Hong Z, Zhong MK: **Association of SCN1A, SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in Chinese Han patients with epilepsy.** *Pharmacogenomics* 2014, **15**(10):1323-1336.
144. Ma CL, Jiao Z, Wu XY, Hong Z, Wu ZY, Zhong MK: **Association between PK/PD-involved gene polymorphisms and carbamazepine-individualized therapy.** *Pharmacogenomics* 2015, **16**(13):1499-1512.
145. Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, Hauser W, Fluss E, Choy E, Kosek E, Amris K, Branco J *et al*: **EULAR revised recommendations for the management of fibromyalgia.** *Annals of the rheumatic diseases* 2016.

146. Makmor-Bakry M, Sills GJ, Hitiris N, Butler E, Wilson EA, Brodie MJ: **Genetic variants in microsomal epoxide hydrolase influence carbamazepine dosing.** *Clinical neuropharmacology* 2009, **32**(4):205-212.
147. Mallinckrodt Brand Pharmaceuticals Inc: **Exalgo (hydromorphone ER).** In: *US Product Monograph.* Hazelwood, MO; 2013.
148. Manna I, Gambardella A, Bianchi A, Striano P, Tozzi R, Aguglia U, Beccaria F, Benna P, Campostrini R, Canevini MP *et al*: **A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy.** *Epilepsia* 2011, **52**(5):e40-44.
149. Martinez C, Blanco G, Ladero JM, Garcia-Martin E, Taxonera C, Gamito FG, Diaz-Rubio M, Agundez JA: **Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use.** *Br J Pharmacol* 2004, **141**(2):205-208.
150. Matic M, Jongen JL, Elens L, de Wildt SN, Tibboel D, Sillevs Smitt PA, van Schaik RH: **Advanced cancer pain: the search for genetic factors correlated with interindividual variability in opioid requirement.** *Pharmacogenomics* 2017, **18**(12):1133-1142.
151. Mazza M, Mazza O, Pazzaglia C, Padua L, Mazza S: **Escitalopram 20 mg versus duloxetine 60 mg for the treatment of chronic low back pain.** *Expert opinion on pharmacotherapy* 2010, **11**(7):1049-1052.
152. McAlpine DE, O'Kane DJ, Black JL, Mrazek DA: **Cytochrome P450 2D6 genotype variation and venlafaxine dosage.** *Mayo Clinic proceedings* 2007, **82**(9):1065-1068.
153. McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperaviciute D, Carrington M, Sills GJ, Marson T, Jia X, de Bakker PI *et al*: **HLA-A\*3101 and carbamazepine-induced hypersensitivity reactions in Europeans.** *The New England journal of medicine* 2011, **364**(12):1134-1143.
154. McCormack M, Gui H, Ingason A, Speed D, Wright GEB, Zhang EJ, Secolin R, Yasuda C, Kwok M, Wolking S *et al*: **Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients.** *Neurology* 2018, **90**(4):e332-e341.
155. McGettigan P, Henry D: **Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies.** *PLoS medicine* 2011, **8**(9):e1001098.
156. Mehta TY, Prajapati LM, Mittal B, Joshi CG, Sheth JJ, Patel DB, Dave DM, Goyal RK: **Association of HLA-B\*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians.** *Indian journal of dermatology, venereology and leprology* 2009, **75**(6):579-582.
157. Methapharm Inc: **Anaprox (naproxen).** In: *CA Product Monograph.* Brantford, ON; 2015.
158. Moon J, Park HK, Chu K, Sunwoo JS, Byun JI, Lim JA, Kim TJ, Shin JW, Lee ST, Jung KH *et al*: **The HLA-A\*2402/Cw\*0102 haplotype is associated with lamotrigine-induced maculopapular eruption in the Korean population.** *Epilepsia* 2015, **56**(10):e161-167.

159. Moon J, Kim TJ, Lim JA, Sunwoo JS, Byun JI, Lee ST, Jung KH, Park KI, Jung KY, Jeon D *et al*: **HLA-B\*40:02 and DRB1\*04:03 are risk factors for oxcarbazepine-induced maculopapular eruption.** *Epilepsia* 2016, **57**(11):1879-1886.
160. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ: **Amitriptyline for neuropathic pain and fibromyalgia in adults.** *The Cochrane database of systematic reviews* 2012, **12**:CD008242.
161. Moore RA, Wiffen PJ, Derry S, Toelle T, Rice AS: **Gabapentin for chronic neuropathic pain and fibromyalgia in adults.** *The Cochrane database of systematic reviews* 2014, **4**:CD007938.
162. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ: **Amitriptyline for neuropathic pain in adults.** *The Cochrane database of systematic reviews* 2015(7):CD008242.
163. Moulin D, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA, Furlan A, Gilron I, Gordon A, Morley-Forster PK *et al*: **Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society.** *Pain research & management : the journal of the Canadian Pain Society = journal de la societe canadienne pour le traitement de la douleur* 2014, **19**(6):328-335.
164. Mouly S, Bloch V, Peoc'h K, Houze P, Labat L, Ksouda K, Simoneau G, Decleves X, Bergmann JF, Scherrmann JM *et al*: **Methadone dose in heroin-dependent patients: role of clinical factors, comedICATIONS, genetic polymorphisms and enzyme activity.** *British journal of clinical pharmacology* 2015, **79**(6):967-977.
165. Murto K, Lamontagne C, McFaul C, MacCormick J, Ramakko KA, Aglipay M, Rosen D, Vaillancourt R: **Celecoxib pharmacogenetics and pediatric adenotonsillectomy: a double-blinded randomized controlled study.** *Can J Anaesth* 2015, **62**(7):785-797.
166. Mushiroda T, Takahashi Y, Onuma T, Yamamoto Y, Kamei T, Hoshida T, Takeuchi K, Otsuka K, Okazaki M, Watanabe M *et al*: **Association of HLA-A\*31:01 screening with the incidence of carbamazepine-induced cutaneous adverse reactions in a Japanese population.** *JAMA Neurol* 2018, **75**(7):842-849.
167. Mylan Pharmaceuticals Inc: **Amitriptyline.** In: *US Product Monograph.* Morgantown, WV; 2016.
168. Mylan Pharmaceuticals Inc: **Flurbiprofen** In: *US Product Monograph.* Morgantown, WV; 2016.
169. Mylan Pharmaceuticals Inc: **Diclofenac Potassium** In: *US Product Monograph.* Morgantown, WV; 2017.
170. National Institute for Health and Care Evidence: **Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy): diagnosis and management. [NICE Guideline 53].** In.; 2007.
171. National Institute for Health and Care Evidence: **Low back pain in adults: early management. [NICE Guideline 88].** In.; 2009.
172. National Institute for Health and Care Evidence: **The pharmacological management of neuropathic pain in adults in non-specialist settings. [NICE Guideline CG173].** In.; 2014.

173. National Institute for Health and Care Excellence: **Non-steroidal anti-inflammatory drugs [NICE Guideline KTT13]**. 2015.
174. National Opioid Use Guideline Group: **Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain. Part A Executive Summary and Background**. In. Place of publication not identified: Michael G. DeGroot National Pain Centre, McMaster University;; 2010: 1 online resource.
175. National Opioid Use Guideline Group: **Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain. Part B Recommendations for Practice**. In. Place of publication not identified: Michael G. DeGroot National Pain Centre, McMaster University;; 2010: 1 online resource.
176. Ng C, Sarris J, Singh A, Bousman C, Byron K, Peh LH, Smith DJ, Tan CH, Schweitzer I: **Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression**. *Human psychopharmacology* 2013, **28**(5):516-522.
177. Nguyen DV, Chu HC, Nguyen DV, Phan MH, Craig T, Baumgart K, van Nunen S: **HLA-B\*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese**. *Asia Pacific allergy* 2015, **5**(2):68-77.
178. Niihara H, Kakamu T, Fujita Y, Kaneko S, Morita E: **HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population**. *The Journal of dermatology* 2012, **39**(7):594-601.
179. Nishizawa D, Fukuda K, Kasai S, Hasegawa J, Aoki Y, Nishi A, Saita N, Koukita Y, Nagashima M, Katoh R *et al*: **Genome-wide association study identifies a potent locus associated with human opioid sensitivity**. *Molecular psychiatry* 2014, **19**(1):55-62.
180. Novartis Pharmaceuticals Canada Inc: **Tegretol (carbamazepine)**. In: *CA Product Monograph*. Dorval, QC; 2014.
181. Novartis Pharmaceuticals Canada Inc: **Voltaren (diclofenac)**. In: *CA Product Monograph*. Dorval, QC; 2014.
182. Novartis Pharmaceuticals Canada Inc: **Voltaren Rapide (diclofenac potassium)**. In: *CA Product Monograph*. Dorval, QC; 2016.
183. Novartis Pharmaceuticals Canada Inc: **Voltaren (diclofenac)**. In: *CA Product Monograph*. Dorval, QC; 2018.
184. Novartis Pharmaceuticals Corporation: **Tegretol (carbamazepine)**. In: *US Product Monograph*. East Hanover, NJ; 2015.
185. Novartis Pharmaceuticals Corporation: **Trileptal (oxcarbazepine)**. In: *US Product Monograph*. East Hanover, NJ; 2019.
186. Ozeki T, Mushiroda T, Yowang A, Takahashi A, Kubo M, Shirakata Y, Ikezawa Z, Iijima M, Shiohara T, Hashimoto K *et al*: **Genome-wide association study identifies HLA-A\*3101 allele as a**

- genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population.** *Human molecular genetics* 2011, **20**(5):1034-1041.
187. Pangarkar SS, Kang DG, Sandbrink F, Bevevino A, Tillisch K, Konitzer L, Sall J: **VA/DoD Clinical Practice Guideline: Diagnosis and Treatment of Low Back Pain.** *Journal of general internal medicine* 2019, **34**(11):2620-2629.
188. Park HJ, Kim YJ, Kim DH, Kim J, Park KH, Park JW, Lee JH: **HLA allele frequencies in 5802 Koreans: Varied allele types associated with SJS/TEN according to culprit drugs.** *Yonsei medical journal* 2016, **57**(1):118-126.
189. Parke-Davis Div of Pfizer Inc: **Neurontin (gabapentin).** In: *US Product Monograph.* NY, NY; 2017.
190. Parke-Davis Div of Pfizer Inc: **Lyrica (pregabalin).** In: *US Product Monograph.* NY, NY; 2018.
191. Pfizer Canada Inc: **Arthrotec (diclofenac / misoprostol).** In: *CA Product Monograph.* Kirkland, QC; 2017.
192. Pfizer Canada Inc: **Celebrex (celecoxib).** In: *CA Product Monograph.* Kirkland, QC; 2017.
193. Pfizer Canada Inc: **Neurontin (gabapentin).** In: *CA Product Monograph.* Kirkland, QC; 2018.
194. Pfizer Canada Inc: **Effexor XR (venlafaxine).** In: *CA Product Monograph.* Kirkland, QC; 2018.
195. Pfizer Canada ULC: **Lyrica (pregabalin).** In: *CA Product Monograph.* Kirkland, QC; 2019.
196. Pfizer Canada ULC: **Celebrex (celecoxib).** In: *CA Product Monograph.* Kirkland, QC; 2019.
197. Pfizer Consumer Healthcare: **Advil (ibuprofen).** In: *CA Product Monograph.* Mississauga, ON; 2017.
198. Pfizer Inc: **Ansaid (flurbiprofen)** In: *US Product Monograph.* New York, NY; 2016.
199. Pfizer Inc: **Flector (diclofenac epolamine).** In: *US Product Monograph.* New York, NY; 2018.
200. Phillips EJ, Sukasem C, Whirl-Carrillo M, Muller DJ, Dunnenberger HM, Chantratita W, Goldspiel B, Chen YT, Carleton BC, George AL, Jr. *et al*: **Clinical Pharmacogenetics Implementation Consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update.** *Clinical pharmacology and therapeutics* 2018, **103**(4):574-581.
201. Pilotto A, Seripa D, Franceschi M, Scarcelli C, Colaizzo D, Grandone E, Niro V, Andriulli A, Leandro G, Di Mario F *et al*: **Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms.** *Gastroenterology* 2007, **133**(2):465-471.
202. Prieto-Perez R, Ochoa D, Cabaleiro T, Roman M, Sanchez-Rojas SD, Talegon M, Abad-Santos F: **Evaluation of the relationship between polymorphisms in CYP2C8 and CYP2C9 and the pharmacokinetics of celecoxib.** *Journal of clinical pharmacology* 2013, **53**(12):1261-1267.
203. Puranik YG, Birnbaum AK, Marino SE, Ahmed G, Cloyd JC, Remmel RP, Leppik IE, Lamba JK: **Association of carbamazepine major metabolism and transport pathway gene**

- polymorphisms and pharmacokinetics in patients with epilepsy.** *Pharmacogenomics* 2013, **14**(1):35-45.
204. Purdue Pharma LP: **Dilaudid (hydromorphone)** In: *US Product Monograph*. Stamford, CT; 2016.
205. Purdue Pharma LP: **Oxycontin (oxycodone)**. In: *US Product Monograph*. Stamford, CT; 2018.
206. Purdue Pharma: **MS-IR (morphine sulphate)**. In: *CA Product Monograph*. Pickering, ON; 2018.
207. Purdue Pharma: **Oxy-IR (oxycodone)**. In: *CA Product Monograph*. Pickering, ON; 2018.
208. Purdue Pharma: **Dilaudid (hydromorphone)**. In: *CA Product Monograph*. Pickering, ON; 2018.
209. Ramirez E, Bellon T, Tong HY, Borobia AM, de Abajo FJ, Lerma V, Moreno Hidalgo MA, Castaner JL, Cabanas R, Fiandor A *et al*: **Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS/TEN are different from those found for the same AED-induced DRESS in the Spanish population.** *Pharmacological research* 2017, **115**:168-178.
210. Ren ZY, Xu XQ, Bao YP, He J, Shi L, Deng JH, Gao XJ, Tang HL, Wang YM, Lu L: **The impact of genetic variation on sensitivity to opioid analgesics in patients with postoperative pain: a systematic review and meta-analysis.** *Pain Physician* 2015, **18**(2):131-152.
211. Reyes-Gibby CC, Shete S, Rakvag T, Bhat SV, Skorpen F, Bruera E, Kaasa S, Klepstad P: **Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene.** *Pain* 2007, **130**(1-2):25-30.
212. Sanis Health Inc: **Naproxen**. In: *CA Product Monograph*. Brampton, ON; 2017.
213. sanofi-aventis US LLC: **Norpramin (desipramine)**. In: *US Product Monograph*. Bridgewater, NJ 2014.
214. Schukro RP, Oehmke MJ, Geroldinger A, Heinze G, Kress HG, Pramhas S: **Efficacy of duloxetine in chronic low back pain with a neuropathic component: a randomized, double-blind, placebo-controlled crossover trial.** *Anesthesiology* 2016, **124**(1):150-158.
215. Scottish Intercollegiate Guidelines Network (SIGN): **Management of chronic pain**. In. Edinburgh: SIGN; 2013.
216. Shams ME, Arneth B, Hiemke C, Dragicevic A, Muller MJ, Kaiser R, Lackner K, Hartter S: **CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.** *Journal of clinical pharmacy and therapeutics* 2006, **31**(5):493-502.
217. Shi YW, Min FL, Liu XR, Zan LX, Gao MM, Yu MJ, Liao WP: **Hla-B alleles and lamotrigine-induced cutaneous adverse drug reactions in the Han Chinese population.** *Basic & clinical pharmacology & toxicology* 2011, **109**(1):42-46.
218. Shi YW, Min FL, Qin B, Zou X, Liu XR, Gao MM, Wang Q, Zhou JQ, Liao WP: **Association between HLA and Stevens-Johnson syndrome induced by carbamazepine in Southern Han Chinese: genetic markers besides B\*1502?** *Basic & clinical pharmacology & toxicology* 2012, **111**(1):58-64.



219. Shi YW, Min FL, Zhou D, Qin B, Wang J, Hu FY, Cheung YK, Zhou JH, Hu XS, Zhou JQ *et al*: **HLA-A\*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions.** *Neurology* 2017, **88**(23):2183-2191.
220. Singkham N, Towanabut S, Lertkachatarn S, Punyawudho B: **Influence of the UGT2B7 -161C>T polymorphism on the population pharmacokinetics of lamotrigine in Thai patients.** *European journal of clinical pharmacology* 2013, **69**(6):1285-1291.
221. Sivem Pharmaceuticals ULC: **Tramadol / Acetaminophen** In: *CA Product Monograph*. St. Laurent, QC; 2015.
222. Skljarevski V, Ossanna M, Liu-Seifert H, Zhang Q, Chappell A, Iyengar S, Detke M, Backonja M: **A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain.** *European journal of neurology* 2009, **16**(9):1041-1048.
223. Skljarevski V, Zhang S, Desai D, Alaka KJ, Palacios S, Miazgowski T, Patrick K: **Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial.** *The journal of pain : official journal of the American Pain Society* 2010, **11**(12):1282-1290.
224. Skljarevski V, Desai D, Liu-Seifert H, Zhang Q, Chappell AS, Detke MJ, Iyengar S, Atkinson JH, Backonja M: **Efficacy and safety of duloxetine in patients with chronic low back pain.** *Spine* 2010, **35**(13):E578-585.
225. SpecGx LLC: **Nortriptyline.** In: *US Product Monograph*. Webster Groves, MO; 2018.
226. Supernus Pharmaceuticals Inc: **Oxtellar XR (oxcarbazepine).** In: *US Product Monograph*. Rockville, MD; 2015.
227. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GA, van Schaik RH, Schalekamp T, Touw DJ *et al*: **Pharmacogenetics: from bench to byte--an update of guidelines.** *Clinical pharmacology and therapeutics* 2011, **89**(5):662-673.
228. Tangamornsuksan W, Chaiyakunapruk N, Somkrua R, Lohitnavy M, Tassaneeyakul W: **Relationship between the HLA-B\*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis.** *JAMA Dermatology* 2013, **149**(9):1025-1032.
229. Taro Pharmaceuticals USA Inc: **Oxcarbazepine** In: *US Product Monograph*. Hawthorne, NY 2014.
230. Tassaneeyakul W, Tiamkao S, Jantararungtong T, Chen P, Lin SY, Chen WH, Konyoung P, Khunarkornsiri U, Auvichayapat N, Pavakul K *et al*: **Association between HLA-B\*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population.** *Epilepsia* 2010, **51**(5):926-930.
231. Teh LK, Selvaraj M, Bannur Z, Ismail MI, Rafia H, Law WC, Sapuan S, Puvanarajah S, Ali PS, Salleh MZ: **Coupling genotyping and computational modeling in prediction of anti-epileptic drugs that cause Stevens Johnson Syndrome and toxic epidermal necrolysis for carrier of HLA-B\*15:02.** *J Pharm Pharm Sci* 2016, **19**(1):147-160.
232. Teva Canada Limited: **Flurbiprofen.** In: *CA Product Monograph*. Toronto, ON; 2015.

233. Teva Canada Limited: **Oxycocet (oxycodone / acetaminophen)**. In: *CA Product Monograph*. Toronto, ON; 2018.
234. Teva Pharmaceuticals USA Inc: **Epitol (carbamazepine)**. In: *US Product Monograph*. North Wales, PA; 2015.
235. Then SM, Rani ZZ, Raymond AA, Ratnaningrum S, Jamal R: **Frequency of the HLA-B\*1502 allele contributing to carbamazepine-induced hypersensitivity reactions in a cohort of Malaysian epilepsy patients**. *Asian Pacific journal of allergy and immunology* 2011, **29**(3):290-293.
236. Tofferi JK, Jackson JL, O'Malley PG: **Treatment of fibromyalgia with cyclobenzaprine: A meta-analysis**. *Arthritis and rheumatism* 2004, **51**(1):9-13.
237. Toh DS, Tan LL, Aw DC, Pang SM, Lim SH, Thirumoorthy T, Lee HY, Tay YK, Tan SK, Vasudevan A *et al*: **Building pharmacogenetics into a pharmacovigilance program in Singapore: using serious skin rash as a pilot study**. *The pharmacogenomics journal* 2014, **14**(4):316-321.
238. Toward Optimized Practice Program: **Guideline for the Evidence-Informed Primary Care Management of Low Back Pain**. In. Edmonton, AB: Institute of Health Economics; 2015.
239. Tribute Pharmaceuticals Canada Inc: **Cambia (diclofenac potassium)**. In: *CA Product Monograph*. London, ON; 2015.
240. Tseng CY, Wang SL, Lai MD, Lai ML, Huang JD: **Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes**. *Clinical pharmacology and therapeutics* 1996, **60**(2):177-182.
241. Uceyler N, Sommer C, Walitt B, Hauser W: **Anticonvulsants for fibromyalgia**. *The Cochrane database of systematic reviews* 2013(10):CD010782.
242. Urquhart DM, Hoving JL, Assendelft WW, Roland M, van Tulder MW: **Antidepressants for non-specific low back pain**. *The Cochrane database of systematic reviews* 2008(1):CD001703.
243. Urquhart DM, Wluka AE, Sim MR, van Tulder M, Forbes A, Gibson SJ, Arnold C, Fong C, Anthony SN, Cicuttini FM: **Is low-dose amitriptyline effective in the management of chronic low back pain? Study protocol for a randomised controlled trial**. *Trials* 2016, **17**(1):514.
244. Urquhart DM, Wluka AE, van Tulder M, Heritier S, Forbes A, Fong C, Wang Y, Sim MR, Gibson SJ, Arnold C *et al*: **Efficacy of Low-Dose Amitriptyline for Chronic Low Back Pain: A Randomized Clinical Trial**. *JAMA internal medicine* 2018, **178**(11):1474-1481.
245. Validus Pharmaceuticals LLC: **Equetro (carbamazepine)**. In: *US Product Monograph*. Parsippany, NJ; 2016.
246. van der Weide J, van Baalen-Benedek EH, Kootstra-Ros JE: **Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype**. *Therapeutic drug monitoring* 2005, **27**(4):478-483.

247. Van Nieuwerburgh FC, Denys DA, Westenberg HG, Deforce DL: **Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms.** *International journal of psychiatry in clinical practice* 2009, **13**(1):345-348.
248. Veefkind AH, Haffmans PM, Hoencamp E: **Venlafaxine serum levels and CYP2D6 genotype.** *Therapeutic drug monitoring* 2000, **22**(2):202-208.
249. Vertical Pharmaceuticals LLC: **Conzip (tramadol ER).** In: *US Product Monograph.* Bridgewater, NJ; 2018.
250. Vevelstad M, Pettersen S, Tallaksen C, Brors O: **O-demethylation of codeine to morphine inhibited by low-dose levomepromazine.** *European journal of clinical pharmacology* 2009, **65**(8):795-801.
251. Waade RB, Hermann M, Moe HL, Molden E: **Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups.** *European journal of clinical pharmacology* 2014, **70**(8):933-940.
252. Wachman EM, Hayes MJ, Brown MS, Paul J, Harvey-Wilkes K, Terrin N, Huggins GS, Aranda JV, Davis JM: **Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome.** *Jama* 2013, **309**(17):1821-1827.
253. Walitt B, Urrutia G, Nishishinya MB, Cantrell SE, Hauser W: **Selective serotonin reuptake inhibitors for fibromyalgia syndrome.** *The Cochrane database of systematic reviews* 2015, **6**:CD011735.
254. Wang Q, Zhou JQ, Zhou LM, Chen ZY, Fang ZY, Chen SD, Yang LB, Cai XD, Dai QL, Hong H *et al*: **Association between HLA-B\*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland.** *Seizure* 2011, **20**(6):446-448.
255. West-Ward Pharmaceuticals Corp: **Codeine Sulfate** In: *US Product Monograph.* Eatontown, NJ; 2016.
256. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, Altman RB, Klein TE: **Pharmacogenomics knowledge for personalized medicine.** *Clinical pharmacology and therapeutics* 2012, **92**(4):414-417.
257. Wiffen PJ, Derry S, Moore RA, McQuay HJ: **Carbamazepine for acute and chronic pain in adults.** *The Cochrane database of systematic reviews* 2011(1):CD005451.
258. Wiffen PJ, Derry S, Moore RA, Aldington D, Cole P, Rice AS, Lunn MP, Hamunen K, Haanpaa M, Kalso EA: **Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews.** *The Cochrane database of systematic reviews* 2013, **11**:CD010567.
259. Williams DG, Patel A, Howard RF: **Pharmacogenetics of codeine metabolism in an urban population of children and its implications for analgesic reliability.** *British journal of anaesthesia* 2002, **89**(6):839-845.

260. Williamson OD, Sagman D, Bruins RH, Boulay LJ, Schacht A: **Antidepressants in the treatment for chronic low back pain: questioning the validity of meta-analyses.** *Pain practice : the official journal of World Institute of Pain* 2014, **14**(2):E33-41.
261. Wong CA, McCarthy RJ, Blouin J, Landau R: **Observational study of the effect of mu-opioid receptor genetic polymorphism on intrathecal opioid labor analgesia and post-cesarean delivery analgesia.** *Int J Obstet Anesth* 2010, **19**(3):246-253.
262. Wu XT, Hu FY, An DM, Yan B, Jiang X, Kwan P, Stefan H, Zhou D: **Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B\*1502 allele among patients in central China.** *Epilepsy & behavior : E&B* 2010, **19**(3):405-408.
263. Wyeth Pharmaceuticals Inc: **Effexor XR (venlafaxine).** In: *US Product Monograph*. Philadelphia, PA; 2018.
264. Yoshida K, Nishizawa D, Ichinomiya T, Ichinohe T, Hayashida M, Fukuda K, Ikeda K: **Prediction formulas for individual opioid analgesic requirements based on genetic polymorphism analyses.** *PLoS one* 2015, **10**(1):e0116885.
265. Zhang Y, Wang J, Zhao LM, Peng W, Shen GQ, Xue L, Zheng XX, He XJ, Gong CY, Miao LY: **Strong association between HLA-B\*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients.** *European journal of clinical pharmacology* 2011, **67**(9):885-887.
266. Zhang W, Yuan JJ, Kan QC, Zhang LR, Chang YZ, Wang ZY: **Study of the OPRM1 A118G genetic polymorphism associated with postoperative nausea and vomiting induced by fentanyl intravenous analgesia.** *Minerva anesthesiologica* 2011, **77**(1):33-39.
267. Zhang J, Zhang L, Zhao X, Shen S, Luo X, Zhang Y: **Association between MDR1/CYP3A4/OPRM1 gene polymorphisms and the post-caesarean fentanyl analgesic effect on Chinese women.** *Gene* 2018, **661**:78-84.
268. Zhou SF: **Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.** *Clinical pharmacokinetics* 2009, **48**(12):761-804.
269. Zhou SF: **Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.** *Clinical pharmacokinetics* 2009, **48**(11):689-723.
270. Zhou BT, Zhou QH, Yin JY, Li GL, Qu J, Xu XJ, Liu D, Zhou HH, Liu ZQ: **Effects of SCN1A and GABA receptor genetic polymorphisms on carbamazepine tolerability and efficacy in Chinese patients with partial seizures: 2-year longitudinal clinical follow-up.** *CNS neuroscience & therapeutics* 2012, **18**(7):566-572.
271. Zhu X, Yun W, Sun X, Qiu F, Zhao L, Guo Y: **Effects of major transporter and metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese patients with epilepsy.** *Pharmacogenomics* 2014, **15**(15):1867-1879.
272. Zwisler ST, Enggaard TP, Mikkelsen S, Verstuyft C, Becquemont L, Sindrup SH, Brosen K: **Lack of association of OPRM1 and ABCB1 single-nucleotide polymorphisms to oxycodone response in postoperative pain.** *Journal of clinical pharmacology* 2012, **52**(2):234-242.

